Skip to main navigation

Fate Therapeutics

0
Skip to content
  • About Us
    • Our Mission
    • Our Cells of Interest
    • Management
    • Board of Directors
  • Pipeline
    • Overview
    • Immuno-Oncology Candidates
      • FT500
      • FT516
      • FT596
      • FT538
      • FT576
      • FT819
    • Immuno-Regulation Candidates
      • ProTmune™
      • FT301
  • Science
    • Ex Vivo Cell Modulation
    • iPSC Platform
    • Manufacturing
    • Publications
  • Collaborations
  • Join Our Team
    • Career Opportunities
    • Vision, Mission, Values
    • Working at Fate
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxies
    • Corporate Governance
    • Stock Information
      • Historic Stock Lookup
    • Investors FAQs
  • Contact
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financial & Filings
      • SEC Filings
      • Annual Reports and Proxies
    • Corporate Governance
    • Stock Information
    • Investors FAQs

SEC Filings

Filing date Form Description View
Dec 24, 2009 D/A View HTML
0001434316-09-000005.pdf
0001434316-09-000005.rtf
Apr 20, 2011 D/A View HTML
0001434316-11-000001.pdf
0001434316-11-000001.rtf
Nov 23, 2009 D View HTML
0001434316-09-000003.pdf
0001434316-09-000003.rtf
Apr 20, 2011 D View HTML
0001434316-11-000002.pdf
0001434316-11-000002.rtf
Aug 21, 2012 D View HTML
0001434316-12-000003.pdf
0001434316-12-000003.rtf
Aug 13, 2013 D View HTML
0001209191-13-040426.pdf
0001209191-13-040426.rtf
May 18, 2015 D View HTML
0001434316-15-000006.pdf
0001434316-15-000006.rtf
Aug 19, 2016 D View HTML
0001434316-16-000007.pdf
0001434316-16-000007.rtf
Dec 08, 2016 D View HTML
0001434316-16-000008.pdf
0001434316-16-000008.rtf
Apr 21, 2020 D View HTML
0001434316-20-000001.pdf
0001434316-20-000001.xls
0001434316-20-000001.rtf

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page Next ›
  • Last page Last »
Displaying 1 - 10 of 605 results

Data provided by Kaleidoscope.

Shareholder Tools

Printed Materials
Email Alerts
Download Library
RSS News Feeds
Print Page
Share
Search

  • Facebook
  • LinkedIn
  • Twitter
  • RSS

© 2023 Fate Therapeutics | 3535 General Atomics Court, Suite 200, San Diego 92121 | 866.875.1833 | LEGAL

MENU
  • About Us
    • Our Mission
    • Our Cells of Interest
    • Management
    • Board of Directors
  • Pipeline
    • Overview
    • Immuno-Oncology Candidates
      • FT500
      • FT516
      • FT596
      • FT538
      • FT576
      • FT819
    • Immuno-Regulation Candidates
      • ProTmune™
      • FT301
  • Science
    • Ex Vivo Cell Modulation
    • iPSC Platform
    • Manufacturing
    • Publications
  • Collaborations
  • Join Our Team
    • Vision, Mission, Values
    • Working at Fate
    • Career Opportunities
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials & Filings
      • SEC Filings
      • Annual Reports and Proxies
    • Corporate Governance
    • Stock Information
      • Historic Stock Lookup
    • Investors FAQs
  • Contact